/PRNewswire/ Intrinsic Therapeutics, Inc., the developer of the Barricaid, an FDA approved medical device proven to significantly reduce reherniations and.
BALTIMORE, Jan. 23, 2024 (GLOBE NEWSWIRE) The Urology Care Foundation, the official foundation of the American Urological Association (AUA), announced.
The Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Industry is poised for remarkable growth, with expectations to reach a substantial valuation of US$ 39.5 billion by 2028. This surge reflects an average compound annual growth rate (CAGR) of 4.7% from 2022 to 2028. In 2022, the market is already on the.
The global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market is expected to reach a valuation of US$ 39.5 Bn in 2028, with demand growing at an average CAGR of 4.7% from 2022 to 2028. In 2022, the target market is set to reach an estimated US$ 30.04 Bn. An increasingly high preference for minimally invas.
The global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market is expected to reach a valuation of US$ 39.5 Bn in 2028, with demand growing at an average CAGR of 4.7% from 2022 to 2028. In 2022, the target market is set to reach an estimated US$ 30.04 Bn. An increasingly high preference for minimally invas.